Literature DB >> 27487740

Interobserver Reproducibility of Percent Gleason Pattern 4 in Prostatic Adenocarcinoma on Prostate Biopsies.

Evita T Sadimin1, Francesca Khani, Mairo Diolombi, Abdelrazak Meliti, Jonathan I Epstein.   

Abstract

In the WHO Classification of Tumours of the Urinary System and Male Genital Organs published in 2016, it was officially recommended that the percent of Gleason pattern 4 (GP4) be reported on pathology reports to better reflect the extent in Gleason score 7 tumors. In this study we assessed the reproducibility of reporting GP4 on prostate biopsies. We analyzed prospectively 422 cores containing GP4 from our consult cases over a period of 2.5 months. The percent pattern 4 was assigned to all the cases in 10% increments from 0% to 100% (with the addition of 5%) by 1 of 4 fellows in urological pathology and by the expert urological pathologist. Out of 422 cores, 32% were an exact match and 75% were within ±10% (weighted κ [κW] value 0.67). Cases were further stratified on the basis of (1) scattered versus clustered GP4 in the background of Gleason pattern 3, (2) continuous versus discontinuous tumor involvement, (3) cribriform/glomeruloid pattern only versus poorly formed/fused pattern versus mixed cribriform and poorly formed/fused pattern, and (4) total tumor involvement of the core (≤10% vs. >10% of the core). No significant differences were observed in the first 3 variables. However, in cases with ≤10% involvement of the core, 61% were within ±10% (κW=0.50) compared with cases with >10% involvement of the core, in which 78% were within ±10% (κW=0.70). In summary, we showed that assessment of percent GP4 was relatively reproducible, with substantial agreement within ±10% in cases. However, with <10% involvement of the core, it was more difficult to assess in smaller foci, with only moderate agreement. Given that in a small focus only a few glands of a given pattern can markedly affect the percent GP4, consideration should be given to not recording percent GP4 in small foci of Gleason score 7 tumors on needle biopsy.

Entities:  

Mesh:

Year:  2016        PMID: 27487740     DOI: 10.1097/PAS.0000000000000714

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

Review 1.  Standardization of reporting discontinuous tumor involvement in prostatic needle biopsy: a systematic review.

Authors:  Min Lu; Shulin Wu; Chin-Lee Wu
Journal:  Virchows Arch       Date:  2021-01-06       Impact factor: 4.064

Review 2.  Future Perspectives and Challenges of Prostate MR Imaging.

Authors:  Baris Turkbey; Peter L Choyke
Journal:  Radiol Clin North Am       Date:  2017-12-09       Impact factor: 2.303

3.  Endoscopic Evidence That Randall's Plaque is Associated with Surface Erosion of the Renal Papilla.

Authors:  Andrew J Cohen; Michael S Borofsky; Blake B Anderson; Casey A Dauw; Daniel L Gillen; Glenn S Gerber; Elaine M Worcester; Fredric L Coe; James E Lingeman
Journal:  J Endourol       Date:  2016-12-20       Impact factor: 2.942

Review 4.  Histopathology of Prostate Cancer.

Authors:  Peter A Humphrey
Journal:  Cold Spring Harb Perspect Med       Date:  2017-10-03       Impact factor: 6.915

5.  Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey.

Authors:  Samson W Fine; Kiril Trpkov; Mahul B Amin; Ferran Algaba; Manju Aron; Dilek E Baydar; Antonio Lopez Beltran; Fadi Brimo; John C Cheville; Maurizio Colecchia; Eva Comperat; Tony Costello; Isabela Werneck da Cunha; Warick Delprado; Angelo M DeMarzo; Giovanna A Giannico; Jennifer B Gordetsky; Charles C Guo; Donna E Hansel; Michelle S Hirsch; Jiaoti Huang; Peter A Humphrey; Rafael E Jimenez; Francesca Khani; Max X Kong; Oleksandr N Kryvenko; L Priya Kunju; Priti Lal; Mathieu Latour; Tamara Lotan; Fiona Maclean; Cristina Magi-Galluzzi; Rohit Mehra; Santosh Menon; Hiroshi Miyamoto; Rodolfo Montironi; George J Netto; Jane K Nguyen; Adeboye O Osunkoya; Anil Parwani; Christian P Pavlovich; Brian D Robinson; Mark A Rubin; Rajal B Shah; Jeffrey S So; Hiroyuki Takahashi; Fabio Tavora; Maria S Tretiakova; Lawrence True; Sara E Wobker; Ximing J Yang; Ming Zhou; Debra L Zynger; Jonathan I Epstein
Journal:  Urol Oncol       Date:  2020-09-15       Impact factor: 2.954

6.  Interchangeability of light and virtual microscopy for histopathological evaluation of prostate cancer.

Authors:  Renata Zelic; Francesca Giunchi; Luca Lianas; Cecilia Mascia; Gianluigi Zanetti; Ove Andrén; Jonna Fridfeldt; Jessica Carlsson; Sabina Davidsson; Luca Molinaro; Per Henrik Vincent; Lorenzo Richiardi; Olof Akre; Michelangelo Fiorentino; Andreas Pettersson
Journal:  Sci Rep       Date:  2021-02-05       Impact factor: 4.379

7.  Development and Validation of an Artificial Intelligence-Powered Platform for Prostate Cancer Grading and Quantification.

Authors:  Wei Huang; Ramandeep Randhawa; Parag Jain; Kenneth A Iczkowski; Rong Hu; Samuel Hubbard; Jens Eickhoff; Hirak Basu; Rajat Roy
Journal:  JAMA Netw Open       Date:  2021-11-01

8.  Computer aided detection in prostate cancer diagnostics: A promising alternative to biopsy? A retrospective study from 104 lesions with histological ground truth.

Authors:  Anika Thon; Ulf Teichgräber; Cornelia Tennstedt-Schenk; Stathis Hadjidemetriou; Sven Winzler; Ansgar Malich; Ismini Papageorgiou
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

9.  The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma.

Authors:  Geert J L H van Leenders; Theodorus H van der Kwast; David J Grignon; Andrew J Evans; Glen Kristiansen; Charlotte F Kweldam; Geert Litjens; Jesse K McKenney; Jonathan Melamed; Nicholas Mottet; Gladell P Paner; Hemamali Samaratunga; Ivo G Schoots; Jeffry P Simko; Toyonori Tsuzuki; Murali Varma; Anne Y Warren; Thomas M Wheeler; Sean R Williamson; Kenneth A Iczkowski
Journal:  Am J Surg Pathol       Date:  2020-08       Impact factor: 6.298

Review 10.  Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer.

Authors:  Meenal Sharma; Hiroshi Miyamoto
Journal:  Transl Androl Urol       Date:  2018-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.